Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a listed condition in the study details.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision v3.5.0 added; revision v3.4.3 removed.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse notice and the older Revision: v3.4.1 entry.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page now displays a government funding lapse notice and the site version was updated to Revision: v3.4.1, which are administrative updates and do not affect core study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check68 days agoChange DetectedShow glossary control added and metadata labels revised (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) replacing the previous QC/Revision label. No core study content, eligibility criteria, or results are affected; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.